Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03767283
Other study ID # HAA
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 5, 2019
Est. completion date December 7, 2021

Study information

Verified date January 2020
Source Assiut University
Contact Ismail Mohamed, proffesor
Phone +01003412279
Email ismailsoliman37@yahoo.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Klebsiella pneumoniae is an important pathogen that frequently causes nosocomial community-acquired and infections, including pneumonia, urinary tract infections, bloodstream infections, pyogenic liver abscesses, and septic shock.

An emerging co-existence of carbapenems and fluoroquinolone resistance in Klebsiella pneumoniae is causing major difficulty in treating infections caused by such pathogen


Description:

Plasmid mediated carbapenem resistance is mainly due to production of carbapenemase which belong to three classes of β-lactamases, the Ambler class A, B and D β -lactamases, among which the New Delhi metallo-β -lactamase has attracted significant attention in the last five years. New Delhi metallo-β -lactamase-1 is a class B metallo-β-lactamase and was first identified from a Klebsiella pneumoniae strain in 2008.

New Delhi metallo-β -lactamase-1 is frequently associated with other resistance genes, such as extended spectrum β- lactamase genes and plasmid-mediated quinolone resistance genes, which allows bacteria to gain resistance to different classes of antimicrobial agents simultaneously.

Plasmids and Integrons are mobile genetic elements that carry antimicrobial resistance genes. Horizontal transfer of those mobile genetic elements has been considered as one of the most important mechanisms for the dissemination of multi-drug resistance among bacteria.

Classification of plasmids on the basis of molecular typing and phylogenetic relatedness may help understand the distribution of plasmid types, the relationships involving plasmids carrying antimicrobial resistance genes. Plasmids can be classified into incompatibility groups by replicon typing or into types (clusters) by restriction fragment length polymorphism analysis.

Integrons act as genetic platform, which allow capture and expression of antibiotic resistance genes. There are 3 classes of integrons that are responsible for multi-drug resistance, which are classified based on the sequence of the integrase gene. Class 1 integrons are the most widespread class in Gram-negative bacteria.

One approach to preventing multi drug resistant infections is combination of two or more antimicrobial drugs during a treatment regimen . The combination of imipenem plus ciprofloxacin had shown Synergistic effect .

Loading of antibacterial agents into nanoparticles is one of the most promising approaches to reduce anti-microbial resistance. Nano formulations could enhance the intracellular bioavailability of the antimicrobial drugs, and, thus, decreasing the development of resistance. Moreover, the potential antibacterial activity of some nanoparticle-forming polymers might further increase the potency of the antibacterial drugs .


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 7, 2021
Est. primary completion date June 10, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Years to 50 Years
Eligibility Inclusion Criteria:

- admitted to intensive care unite

Exclusion Criteria:

- healthy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Assiut University Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Al-Marzooq F, Mohd Yusof MY, Tay ST. Molecular Analysis of Antibiotic Resistance Determinants and Plasmids in Malaysian Isolates of Multidrug Resistant Klebsiella pneumoniae. PLoS One. 2015 Jul 23;10(7):e0133654. doi: 10.1371/journal.pone.0133654. eCollection 2015. — View Citation

Chang CY, Lin HJ, Chang LL, Ma L, Siu LK, Tung YC, Lu PL. Characterization of Extended-Spectrum ß-Lactamase-Carrying Plasmids in Clinical Isolates of Klebsiella pneumoniae from Taiwan. Microb Drug Resist. 2017 Jan;23(1):98-106. doi: 10.1089/mdr.2015.0212. Epub 2016 May 5. — View Citation

Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013 Mar;31(3):177-84. doi: 10.1016/j.tibtech.2012.12.006. Epub 2013 Jan 18. Review. — View Citation

Zhao JY, Zhu YQ, Li YN, Mu XD, You LP, Xu C, Qin P, Ma JL. Coexistence of SFO-1 and NDM-1 ß-lactamase genes and fosfomycin resistance gene fosA3 in an Escherichia coli clinical isolate. FEMS Microbiol Lett. 2015 Jan;362(1):1-7. doi: 10.1093/femsle/fnu018. Epub 2014 Dec 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary effect of combined antibiotic therapy on resistance determination of minimum inhibitory concentration to antibiotics before and after combination 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06262009 - Dynamics of AMR Spread, Persistence and Evolution Between Humans, Animals and Their Environment
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT04460313 - Nasopharyngeal Carriage of S. Pneumoniae N/A
Active, not recruiting NCT03208725 - Childhood Acute Illness and Nutrition Network
Completed NCT03963297 - Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination
Active, not recruiting NCT05027893 - Complications After Lower Third Molar Surgery N/A
Not yet recruiting NCT04795518 - The Pattern of Antibiotic Prescription for Children Among a Group of Pediatric Dentists.
Completed NCT05551988 - Predictors of Foot Amputation in Diabetic Foot Ulcers
Completed NCT03061097 - Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization Phase 1
Withdrawn NCT03391674 - Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization N/A
Recruiting NCT04107194 - Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection. Phase 3
Completed NCT03884348 - Tailored H. Pylori Eradication Based on Clarithromycin Resistance
Completed NCT04926935 - Bloodstram Infections in ICU. Single Centre Observational Study.
Not yet recruiting NCT04269174 - The Utility of Biofire Filmarray in Evaluation of Entero Pathogens Triggers in Patients With Chronic Diarrhea
Completed NCT03167398 - Fecal Microbiota Transplantation for Eradication of CRE Phase 1/Phase 2
Completed NCT03866291 - ESBL in Patients Returning to Sweden With Traveller's Diarrhoea
Completed NCT01902589 - Resistance of Helicobacter Pylori to Antibiotics in Children N/A
Not yet recruiting NCT04593368 - Fecal Microbiome Transplantation (FMT) in Pediatric Patients Colonized With Antibiotic-resistant Pathogens Before Hematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT03063437 - A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization Phase 2
Active, not recruiting NCT03140410 - Linezolid-resistant Staphylococcus Epidermidis in ICU and Risk Factors Analysis N/A